A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo

NCT06015308 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

224

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatitis Atopic

Interventions

DRUG: Amlitelimab
DRUG: Placebo
BIOLOGICAL: Tdap vaccine
BIOLOGICAL: PPS vaccine

Sponsor

Sanofi